Olotu Titilayo, Ferrell Jessica M
Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA.
School of Biomedical Sciences, Kent State University, Kent, OH 44242, USA.
Microorganisms. 2024 Dec 3;12(12):2488. doi: 10.3390/microorganisms12122488.
Probiotics are studied for their therapeutic potential in the treatment of several diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD). Part of the significant progress made in understanding the pathogenesis of steatosis has come from identifying the complex interplay between the gut microbiome and liver function. Recently, probiotics have shown beneficial effects for the treatment and prevention of steatosis and MASLD in rodent models and in clinical trials. Numerous studies have demonstrated the promising potential of lactic acid bacteria, especially the genus . is a prominent bile acid hydrolase bacterium that is involved in the biotransformation of bile acids. This genus' modulation of the gut microbiota also contributes to overall gut health; it controls gut microbial overgrowth, shapes the intestinal bile acid pool, and alleviates inflammation. This narrative review offers a comprehensive summary of the potential of in the gut-liver axis to attenuate steatosis and MASLD. It also highlights the roles of in hepatic lipid metabolism, insulin resistance, inflammation and fibrosis, and bile acid synthesis in attenuating MASLD.
益生菌因其在治疗包括代谢功能障碍相关脂肪性肝病（MASLD）在内的多种疾病方面的治疗潜力而受到研究。在理解脂肪变性发病机制方面取得的部分重大进展来自于确定肠道微生物群与肝功能之间的复杂相互作用。最近，益生菌在啮齿动物模型和临床试验中已显示出对治疗和预防脂肪变性及MASLD的有益作用。大量研究证明了乳酸菌，尤其是[具体菌属未给出]属的有前景的潜力。[具体菌属未给出]是一种参与胆汁酸生物转化的重要胆汁酸水解酶细菌。该菌属对肠道微生物群的调节也有助于整体肠道健康；它控制肠道微生物过度生长，塑造肠道胆汁酸池，并减轻炎症。这篇叙述性综述全面总结了[具体菌属未给出]在肠 - 肝轴中减轻脂肪变性和MASLD的潜力。它还强调了[具体菌属未给出]在肝脏脂质代谢、胰岛素抵抗、炎症和纤维化以及胆汁酸合成在减轻MASLD中的作用。
